Abstract
The posterior reversible encephalopathy syndrome (PRES), a complex of cerebral disorders including headache, seizures, visual disturbances, is associated with a variety of conditions in which blood pressure rises acutely. Arterial hypertension can occur in systemic administration of bevacizumab. A few cases of systemic injection of bevazicumab-induced PRES have been reported. In this article, we first report on a patient who developed PRES following intravitreal bevazicumab.
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects*
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Choroidal Neovascularization / drug therapy
-
Choroidal Neovascularization / etiology
-
Humans
-
Injections
-
Macular Degeneration / complications
-
Male
-
Posterior Leukoencephalopathy Syndrome / chemically induced*
-
Visual Acuity
-
Vitreous Body
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab